Detailed price information for Bio-Path Holdings (BPTH-Q) from The Globe and Mail including charting and trades.

Researchers determined discontinuing BTK inhibitors appears to be more common than discontinuing venetoclax plus obinutuzumab for older patients with CLL.

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...